| Patient | Wilma Mankiller |
|---|---|
| Date of birth | 1991-11-18 |
| Identifiers | MRN HR-ML052-SYN; SSN (made up) 000-52-4183 |
| Document date | 2026-03-23 |
| Author | Rena Hawkfeather-Lindqvist, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Two-week review: antibody, nerve stimulation and imaging results; neuromuscular neurology seen today. [S]
Ms. Mankiller returns two weeks after her first visit. On pyridostigmine 30 mg three times daily her eyelids lift for two to three hours after each dose, but double vision returns by evening and her arms still tire when she brushes her hair; she has mild stomach cramps and looser stools after doses. She has had no breathlessness, choking or weak cough. The acetylcholine receptor antibody test is strongly positive. The chest CT and kidney ultrasound were done last week. This morning she saw Dr. Okafor-Delaney of neuromuscular neurology, whose nerve stimulation test showed the typical decrement, and they agreed a plan: a higher pyridostigmine dose, prednisone started low and raised slowly, azathioprine once the screening tests are back, and an assessment for thymectomy. She asked that her blood tests be drawn near home where possible, and wants to understand each medicine before she takes it. She says the polycystic kidney disease is not new to her. [S]
| Element | Detail |
|---|---|
| Diagnosis | Generalized myasthenia gravis, AChR antibody 6.8 nmol/L, decrement on nerve stimulation; MGFA class IIa; MG-ADL 7 |
| Imaging | No thymoma on chest CT; kidney ultrasound: polycystic kidneys, Mayo Imaging Class 1B |
| Starting today | Pyridostigmine 60 mg four times daily; prednisone 10 mg rising weekly; calcium and vitamin D |
| Vaccines today | PCV20 and recombinant zoster dose 1, before immunosuppression |
| System | Result | Finding |
|---|---|---|
| Eyes | Positive | Drooping eyelids and double vision by evening |
| Musculoskeletal | Positive | Arms and neck tire with use; leg aches after the operations |
| Gastrointestinal | Positive | Cramps and loose stools after pyridostigmine; no trouble swallowing |
| Respiratory | Negative | No breathlessness lying flat; cough strong |
| Psychiatric | Negative | Worried but coping; PHQ-2 score 1 |
5 systems reviewed. [S]
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Pyridostigmine bromide 30 mg oral tablet, one tablet three times daily with meals as a trial; take 30 to 45 minutes before eating | One tablet three times daily | Oral route | 2026-03-09 to 2026-03-23 | completed | S |
| Pyridostigmine bromide 60 mg oral tablet, one tablet four times daily while awake, 30 to 45 minutes before meals | One tablet four times daily while awake | Oral route | 2026-03-23 to 2026-10-12 | completed | S |
| Prednisone 10 mg oral tablet, 10 mg each morning, rising by 10 mg each week to 40 mg each morning, then held at 40 mg | Once each morning; dose as directed | Oral route | 2026-03-23 to 2026-07-13 | completed | S |
| Calcium carbonate 1250 mg (500 mg elemental calcium) oral tablet, one tablet daily with food | One tablet daily with food | Oral route | 2026-03-23 | active | S |
| Cholecalciferol (vitamin D3) 1000 units (0.025 mg) oral tablet, one tablet daily | One tablet daily | Oral route | 2026-03-23 | active | S |
| Acetaminophen 500 mg oral tablet, one or two tablets up to three times daily as needed for leg pain | One or two tablets up to three times daily as needed | Oral route | 2025-09-15 | active | S |
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-03-23 | Body height | 163 | cm | S |
| 2026-03-23 | Body weight | 61.6 | kg | S |
| 2026-03-23 | Body mass index (BMI) [Ratio] | 23.2 | kg/m2 | S |
| 2026-03-23 | Systolic blood pressure | 124 | mm[Hg] | S |
| 2026-03-23 | Diastolic blood pressure | 80 | mm[Hg] | S |
| 2026-03-23 | Heart rate | 76 | /min | S |
| 2026-03-23 | Respiratory rate | 16 | /min | S |
| 2026-03-23 | Body temperature | 36.6 | Cel | S |
| 2026-03-23 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-03-23 | Acetylcholine receptor binding Ab [Moles/volume] in Serum | 6.8 | nmol/L | 0.02 nmol/L or less is negative | High | S |
| 2026-03-23 | Forced vital capacity [Volume] Respiratory system | 3.25 | L | Lower limit of normal about 2.9 L for her age, sex and height | Normal | S |
| 2026-03-23 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 1 | {score} | S |
Vital signs recorded on 2026-03-23; see the Vital Signs section. [S]
| System | Finding |
|---|---|
| General | Well; blood pressure 124/80 mm Hg |
| Eyes | Left ptosis after 40 seconds of upgaze; diplopia on sustained right gaze |
| Neurological | Neck flexion 4 of 5; deltoids fatigue after 45 seconds of arm abduction; speech becomes nasal after counting to 40; reflexes normal |
| Respiratory | Single-breath count to 30; FVC 3.25 L |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Drooping eyelids and double vision for six weeks, worse in the evening, with fatigable weakness of the arms and neck, tiring when chewing and a nasal voice after long talks; a disorder of the neuromuscular junction suspected | resolved | confirmed | H53.2 | S — Synthetic presenting problem, resolved at the second visit when antibodies and nerve testing established myasthenia gravis. |
| Generalized myasthenia gravis, acetylcholine receptor antibody positive, MGFA class IIa, without thymoma; synthetic modern detail linked to her documented myasthenia gravis of 1980 | active | confirmed | G70.00 | S — Synthetic antibody level, electrodiagnosis, class and treatment; the diagnosis less than a year after the crash, and recovery with Cherokee medicine people, surgery and drug therapy, are documented (D). |
| Autosomal dominant polycystic kidney disease (hereditary, as she has described it), with normal kidney function; to be staged | active | confirmed | Q61.2 | S — The hereditary polycystic kidney disease is documented (D) from her later public account; its detection before the index date, and every value, are synthetic. |
| Recovery from major trauma in a head-on car crash last year: fractures of both legs, ribs and face, with many operations; walks independently, with a cane on rough ground | active | confirmed | Z87.81 | S — The crash, the operations and the injuries are documented (D); the current function is synthetic. |
| Long-term glucocorticoid therapy for myasthenia gravis, with monitoring of glucose, blood pressure, weight, bone health, mood, sleep, eyes and infection | active | confirmed | Z79.52 | S — Synthetic treatment plan. |
Protocol monitoring: items the monitoring protocol calls for at this visit. [S]
| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Laboratory | Acetylcholine receptor binding antibodies | At diagnosis | Completed today | 6.8 nmol/L, positive (drawn at the first visit) |
| Laboratory | MuSK antibodies | If AChR antibodies are negative | Not indicated | AChR antibodies positive |
| Examination | Repetitive nerve stimulation | At diagnosis | Completed today | 22 percent decrement in the nasalis and 18 percent in the trapezius at neuromuscular neurology |
| Examination | Single-fiber EMG | If antibodies and nerve stimulation are not diagnostic | Not indicated | Diagnosis already confirmed |
| Imaging | CT of the chest for thymoma | At diagnosis | Up to date | Five days ago: no thymoma; residual thymic tissue for age |
| Laboratory | TSH | At diagnosis | Up to date | 1.9 mIU/L at the first visit |
| Imaging | Forced vital capacity and negative inspiratory force | Every visit while weak, and with any breathing or swallowing symptom | Completed today | FVC 3.25 L; negative inspiratory force -68 cm H2O; single-breath count 30 |
| Examination | Myasthenic crisis warning signs | Every visit | Completed today | No breathlessness lying flat, weak cough, choking or slurred speech; reviewed again with her |
| Survey | MG-ADL score | Every visit | Completed today | 7 of 24 (eyelids, double vision, chewing, brushing hair); no LOINC code, so recorded here |
| Survey | Depression screen (PHQ-2) | At intervals | Completed today | PHQ-2 score 1 |
| Medication safety | Pyridostigmine side effects | Every visit | Completed today | Cramps and loose stools, mild; taken before meals |
| Medication safety | Medicines that can worsen myasthenia gravis | At diagnosis and with every new prescription | Completed today | Wallet card and list given: fluoroquinolones, aminoglycosides, macrolides, magnesium by vein, beta-blockers, telithromycin and others |
| Laboratory | Screening before immunosuppression: hepatitis B, tuberculosis and TPMT | Before azathioprine | Ordered | Drawn today at the clinic |
| Laboratory | Hemoglobin A1c before glucocorticoids | Baseline, then periodically | Up to date | 5.3 percent at the first visit |
| Medication safety | Vaccination before immunosuppression | Before starting immunosuppressive drugs | Completed today | PCV20 and recombinant zoster dose 1 today; no live vaccines from now on |
| Medication safety | Pregnancy and contraception on prednisone and azathioprine | Before starting and yearly | Completed today | Urine pregnancy test negative; she reports reliable contraception; pregnancy to be planned with neuromuscular neurology |
| Laboratory | eGFR and urine albumin-to-creatinine ratio | Yearly in ADPKD with normal function | Up to date | eGFR 102 and urine albumin 14 mg/g at the first visit |
| Imaging | Kidney imaging with total kidney volume (Mayo Imaging Classification) | At diagnosis or first assessment | Up to date | Ultrasound five days ago: htTKV 364 mL/m, class 1B; tolvaptan not indicated |
| Examination | Blood pressure | Every visit | Completed today | 124/80 mm Hg in clinic; home readings to start |
| Referral | Neuromuscular neurology | Once, then through treatment | Completed today | Seen today; recommendations in the consultation note |
| Referral | Thoracic surgery for thymectomy | Once stable | Ordered | Assessment visit in about four weeks |
| Self-management | Home blood pressure, water intake, salt, and care close to home | Every visit | Completed today | Home monitor shown; blood tests to be drawn at the Cherokee Nation clinic near her home where possible |
Goal progress:
Immunizations given today: Pneumococcal conjugate vaccine PCV20, before immunosuppression; Recombinant zoster vaccine, dose 1 of 2, before immunosuppression [S]
Guideline basis: Narayanaswami P, et al. International Consensus Guidance for Management of Myasthenia Gravis: 2020 Update. Neurology 2021;96(3):114-122 (2020); Sanders DB, et al. International consensus guidance for management of myasthenia gravis: Executive summary. Neurology 2016;87(4):419-425 (2016); Cautionary Drugs (medicines that may worsen myasthenia gravis) (2026); KDIGO 2025 Clinical Practice Guideline for the Evaluation, Management, and Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD). Kidney Int 2025;107(2S):S1-S239 (2025)
Follow-up: Neuromuscular neurology nurse call in one week as prednisone rises. Thoracic surgery assessment in about four weeks. Review here in six weeks with blood count, chemistry, FVC and DXA. Next scheduled visit 2026-05-04: six-week review on pyridostigmine and prednisone: strength, breathing, glucose and blood pressure, bone density, start of azathioprine, and the thymectomy plan. [S]